Semanteon Capital Management LP Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Semanteon Capital Management LP acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 105,868 shares of the biopharmaceutical company’s stock, valued at approximately $1,131,000.

Several other hedge funds have also recently made changes to their positions in the stock. Assenagon Asset Management S.A. purchased a new stake in Amicus Therapeutics during the second quarter valued at approximately $8,386,000. M&G Plc increased its holdings in Amicus Therapeutics by 12.4% during the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock valued at $7,485,000 after buying an additional 82,728 shares during the last quarter. Edgestream Partners L.P. increased its holdings in Amicus Therapeutics by 1,290.4% during the first quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock valued at $3,183,000 after buying an additional 250,734 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Amicus Therapeutics by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after buying an additional 7,304 shares during the last quarter. Finally, Fiera Capital Corp increased its holdings in Amicus Therapeutics by 1.1% during the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after buying an additional 58,113 shares during the last quarter.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 22,500 shares of company stock worth $244,875 over the last 90 days. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD traded up $0.13 during midday trading on Monday, reaching $11.82. 23,344 shares of the company were exchanged, compared to its average volume of 2,721,384. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The business’s fifty day moving average is $11.19 and its two-hundred day moving average is $10.56. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The stock has a market cap of $3.50 billion, a PE ratio of -23.86 and a beta of 0.69.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. During the same quarter in the prior year, the business earned ($0.15) earnings per share. Amicus Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. As a group, analysts predict that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have commented on FOLD shares. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 23rd. Bank of America upped their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Friday, September 20th. JPMorgan Chase & Co. dropped their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 16th. Finally, Morgan Stanley dropped their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.13.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.